Showing 8121-8130 of 10397 results for "".
- Baricitinib Enhances Phototherapy Efficacy in Adults with Active Vitiligohttps://practicaldermatology.com/news/baricitinib-enhances-phototherapy-efficacy-in-severe-atopic-dermatitis/2471046/Baricitinib combined with narrowband UV-B achieved a modest reduction in disease severity in adults with severe, active nonsegmental vitiligo, but did not meet the prespecified threshold for sufficient repigmentation, new research revealed. The trial enrolled 49 adul
- IgE Identified as Key Mediator in Psoriasis and Atherosclerosis Comorbidityhttps://practicaldermatology.com/news/ige-identified-as-key-mediator-in-psoriasis-and-atherosclerosis-comorbidity/2471009/A new review points to immunoglobulin E (IgE) as a potential central player in the overlapping mechanisms of psoriasis and atherosclerosis. Researchers writing in Biomedicine and Pharmacotherapy proposed IgE-mediated mast cell (MC) activation as a significant contributor to the progressio
- Analysis: FDA Approvals Highlight Disparities in Oncology Outcomes by Ancestryhttps://practicaldermatology.com/news/analysis-fda-approvals-highlight-disparities-oncology-outcomes-ancestry/2470889/Patients of African ancestry remain underrepresented in eligibility for biomarker-driven precision oncology therapies, according to a new study in JAMA Dermatology. The retrospective analysis of 59,433 patients with solid cancers looked at genetic sequencing data from MSK-IMPACT a
- PPIs, H2RAs Can Increase Psoriasis Risk for Patients With GI Diseaseshttps://practicaldermatology.com/news/ppis-h2ras-can-increase-psoriasis-risk-patients-gi-diseases/2470871/Prolonged use of proton pump inhibitor (PPI) or histamine-2 receptor antagonists (H2RA) is associated with the risk of psoriasis among patients with gastrointestinal diseases, according to a new study published in the Korean Journal of Internal Medicine. The study included 3,662 p
- Review Examines Potential of AI Tools for Physician Burnouthttps://practicaldermatology.com/news/streamlining-charting-ai-tools/2470864/Patient documentation tools powered by AI have the potential to alleviate burnout among dermatologists by streamlining administrative tasks, according to a recent review published in the Journal of Drugs in Dermatology. "The prevalence of burnout among United States (US) dermatolo
- Higher WWI Linked to Increased Mortality Rates in Psoriasis Patientshttps://practicaldermatology.com/news/higher-wwi-linked-increased-mortality-rates-psoriasis-patients/2470869/New research indicates a strong positive correlation between weight-adjusted waist index (WWI) and all-cause mortality in psoriasis patients. Researchers at Wenzhou Medical University in China published “Weight-Adjusted Waist Index, Psoriasis, and All-Cause Mortality: Findings from the NHA
- Analysis: No Risk Differences in MACE and VTE Among Biologics for Psoriatic Diseasehttps://practicaldermatology.com/news/analysis-no-risk-differences-mace-and-vte-among-biologics-psoriatic-disease/2470809/A recent cohort analysis revealed no significant differences in the risks of major adverse cardiovascular events (MACE) and venous thromboembolic events (VTE) among biologic-naïve patients with psoriasis or psoriatic arthritis (PsA) treated with different classes of biologics. Researchers
- Knight Dermatology Institute Partners With Forefront Dermatologyhttps://practicaldermatology.com/news/knight-dermatology-institute-partners-forefront-dermatology/2470808/Knight Dermatology Institute (KDI) and Forefront Dermatology have formed a partnership, Physician Growth Partners (PGP) announced in a press release. Based in Orlando, Florida, KDI is a medically and surgically driven practice with a core focus on skin cancer detection, prevention, and tre
- Castle Biosciences' Test Identifies AD Patients Likely to Achieve EASI90https://practicaldermatology.com/news/castle-biosciences-test-identifies-ad-patients-likely-achieve-easi90/2470795/Castle Biosciences has announced its investigational gene expression profile test for atopic dermatitis (AD) may identify patients likely to achieve a 90% or greater reduction in Eczema Area and Severity Index (EASI) scores within three months of targeted therapy initiation. Currently, ov
- Neurotrimin Identified as Key Target for Keloid Treatment: Analysishttps://practicaldermatology.com/news/neurotrimin-identified-key-target-keloid-treatment-analysis/2470778/Researchers for a new genetic study have identified seven proteins as potential drug targets for the treatment of keloids, with neurotrimin (NTM) emerging as a particularly significant finding. Publishing in the Journal of Investigative Dermatology, the study design employed a two-sample M